50 This is further supported by our PFS analysis, which shows no significant benefit of first‐line nilotinib, although there is a slight trend towards an advantage of initial nilotinib treatment (imatinib‐matched 88.0% vs. nilotinib 92.9%, respectively).
← all excerpts
Clinical efficacy and safety of first-line nilotinib or imatinib therapy in patients with chronic myeloid leukemia-Nationwide real life data.
1
—
—